变应原特异性免疫治疗(SIT)是目前已知的唯一能改变变态反应性疾病患者对变应原免疫的类型，并有可能治愈变态反应性疾病的方法。通常是通过反复多次皮下注射，即皮下免疫治疗(SCIT)，诱导患者对变应原的耐受，但因其不良反应较大，并有可能引起过敏性休克等原因而使其应用受到限制。近来通过舌下含服的方法进行免疫治疗，即舌下免疫治疗(SLIT)，引起了临床上广泛的兴趣。与SCIT相比，SLIT完全由患者自己使用药物，因此更方便，临床研究也证实这种方法更安全，也更有效。而且与药物治疗相比，SLIT可以显著降低临床费用，减轻患者和社会的负担。但是SLIT诱导免疫耐受的确切机制目前仍不清楚。
【摘要】 目的 研究Monaco治疗计划系统中不同参数设置对容积旋转调强放射治疗(VMAT)计划质量的影响，得出更合理的治疗计划参数设置以提高VMAT治疗质量。 方法 2010年1-5月间治疗3例患者，为食管癌、宫颈癌和鼻咽癌各1例，分别设置不同的计划参数进行容积旋转调强计划优化，通过多种评估指标比较各VMAT计划质量的差异，得出临床所需的MSC、MSS、SSF、Sm、MMS和MDR共6个治疗计划参数对VMAT治疗质量的影响。 结果 MSC、MSS和SSF的3个参数对VMAT治疗质量不产生影响，有影响的Sm、MMS和MDR参数中，随着Sm和MMS值的增大，VMAT计划的剂量分布逐渐变差，但控制点数、机器跳数和照射时间均逐渐减小；随着MDR值增大，VMAT治疗的剂量分布先逐渐变差后不变，控制点数和机器跳数均是先增大后不变，而照射时间是先减小后不变。 结论 Sm、MMS和MDR 3个参数对VMAT计划质量有较大影响，对不同的患者，设置合适的Sm、MMS和MDR值对提高计划质量非常重要。【Abstract】 Objective To investigate the impacts of parameter settings on the quality of plans for the volumetric modulated arc therapy (VMAT) with Monaco treatment planning system. Methods Three patients who underwent VMAT from January to May 2010 were selected. The planning optimizations were processed by setting different planning parameters, including MSC, MSS, SSF, Sm, MMS and MDR, respectively. Then the quality of each plan with a certain set of parameters was evaluated by various evaluation indexes. The differences of quality among different plans were analyzed by comparing these indexes. Results There was no influence on the quality of VMAT planning for the parameter MSC, MSS and SSF to be set with different values. However, the other three parameters, MSC, MSS and SSF , affected the quality of VMAT planning with different values. Along with the aggrandizement of Sm and MMS value, the dose distribution of VMAT plans gradually became bad, while the number of control points, machine monitor units and irradiation time were gradually reduced. And along with the aggrandizement of MDR value, the dose distribution of VMAT plans became bad gradually until a constant state was reached, and both the number of control points and machine monitor units increased at first and then kept constant, while irradiation time decreased at first and then kept constant. Conclusion The selections of parameter Sm, MMS and MDR impact the quality of VMAT planning greatly. It is very important to set the suitable value of Sm, MMS and MDR to get the best planning quality for patients with different complexity.
【摘要】 目的 研究千伏级锥形束CT（kV-cone beam CT，kV-CBCT）影像用于鼻咽癌调强放射治疗计划剂量计算的可行性和精确度。 方法 2010年7-9月7例鼻咽癌患者 ，获取每例患者的第1天放射治疗时的kV-CBCT影像。用CIRS062密度模体和患者自身特定区域亨氏单位值（hounsfield unit，HU）映射的两种方法重新刻度亨氏单位值-相对电子密度（HU-RED）表，分别进行剂量计算，并与在传统扇形束CT（FBCT）影像上的原放射治疗计划结果进行对比，包括辐射剂量分布、靶区和危及器官的剂量体积直方图（DVH）。 结果 kV-CBCT影像的治疗计划和原治疗计划在剂量分布和DVH上有较好的一致性。在剂量分布的比较上采用了γ分析（2%/2 mm标准的通过率），用基于模体的HU-RED表得到的治疗计划与原治疗计划对比，在经过等中心冠状面、矢状面和横断面的通过率分别为92.7%±3.5%、95.1%±3.1%和95.7%±3.4%，用基于患者的HU-RED表得到治疗计划与原治疗计划对比的通过率分别为94.8%±2.7%、96.6%±2.9%和97.4%±2.7%。DVH的统计数据表明，两种方法得到的kV-CBCT治疗计划和原治疗计划相比较，靶区和危及器官剂量偏差大多数在2%以内。有1例因在横断面发生了明显的旋转误差，导致在横断面的通过率很低，DVH统计数据较原计划偏差较大。 结论 kV-CBCT影像可以用来做辐射剂量计算，基于患者自身影像生成的HU-RED表的治疗计划较原治疗计划有更高的符合度。【Abstract】 Objective To evaluate the feasibility and accuracy of dose calculation based on cone beam CT (CBCT) data sets for intensity modulated radiation therapy (IMRT) planning of nasopharyngeal cancer (NPC). Methods Seven NPC patients were selected. The kV-CBCT images for each patient were acquired on the first treatment day. Two correction strategies were used to generate the cone beam HU value vs relative electron density calibration tables which named CIRS062 phantom based HU-RED tables and patient specific HU-RED tables respectively for dose calculation. The dose distributions and dose volume histograms (DVHs) of the target and organs at risk (OAR) based on kV-CBCT images were compared to the plans based on the fan-beam CT (FBCT). Results The DVH and dose distribution comparison between plans based on the FBCT and those on the CBCT showed good agreements. The γ analysis with a criterion of 2 mm/2% was used for the comparison of dose distribution at the coronal plane, sagital plane and cross plane through the isocenter point. The passing rate from phantom based HU-RED tables were (92.7±3.5) %, (95.1±3.1) %, and (95.7±3.4)%, respectively. The passing rates from the patient specific HU-RED tables were (94.8±2.7) %, (96.6±2.9) %, and (97.4±2.7) %, respectively. The dose difference between plans based on CBCT and those based on FBCT was within 2% at most patients by analyzing DVH based parameters. Only one patient who had significant rotation setup error resulted in the low passing rate and disagreement in DVH. Conclusion The CBCT images can be used to do dose calculation in IMRT planning of NPC. The differences between plans based on HU-RED tables generated by specific patient and the original plans are less than those between plans based on CIRS062 phantom based HU-RED tables and the original plans.
Objective To investigate the effects of FasL gene-modified dendritic cell (DC) on the airway inflammation in mice sensitized/challenged by house dust mite (HDM) allergen.Methods FasL gene-modified DC (FasL-DC) and control DC (nontransfection DC) were administrated into HDM sensitized and challenged mice by intratracheal injection respectively，then HDM sensitized and challenged mice were sacreificed two days later.Total and differentiation cell counts and levels of interleukin-4（IL-4），IL-5 and interferon-γ(IFN-) in bronchoalveolar lavage fluid (BALF) were detected and lung histological features were observed.Results After administration of FasL-DC，lung allergic inflammation was ameliorated while total cell counts，the percentage of eosinophil ,the levels of IL-4 and IL-5 in BALF decreased and the level of IFN- in BALF increased.Conclusion Administrating FasL-DC into HDM sensitized/challenged mice can inhibit Th2 cells activation and ameliorate airway allergic inflammation.
ObjectiveTo understand the trend and problems of asthma treatment in different levels of hospitals in Chongqing, and to provide objective basis for more refined and standardized asthma management. MethodsThe outpatient and inpatient asthma diagnosis and treatment data of four hospitals of different grades in Chongqing from 2017 to 2021 were extracted by medical big data capture platform, and the trend of outpatient and prescription changes was analyzed retrospectively according to natural year. ResultsThere were 19514 outpatients asthma visits in the four hospitals, of whom 11816 (60.6%) were female. There were 1875 hospitalizations, of which 1117 (59.6%) were female. ① Changes of asthma visit mode: From 2017 to 2019, the number of outpatient asthma visits and the proportion of asthma in the total outpatient volume increased, decreased significantly in 2021, and basically recovered to the level of 2019 in 2022. Asthma hospitalizations in tertiary hospitals showed a decreasing trend, while those in secondary hospitals increased significantly. The proportion of asthma patients who chose outpatient treatment in the four hospitals increased year by year, among which the increase was more significant in non-tertiary teaching hospitals, and the proportion of asthma acute attack in outpatient and inpatient treatment increased. ② Changes of medication pattern: The rate of inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) prescription in outpatient department increased year by year, the highest was 48.6%, but the rate of short-acting β2-agonists (SABA) prescription also increased year by year, especially in secondary hospitals, the rate of SABA prescription in secondary hospitals reached 39.7%. The proportion of hospitalized asthma patients treated with inhaled corticosteroids (85.1%) was higher than that of intravenous corticosteroids (50.9%), and the proportion of intravenous theophylline prescription was as high as 91.7%, while the proportion of nebulized SABA prescription was 71.4%. ConclusionsThe trend of asthma diagnosis and treatment is that the number of outpatients and the use of ICS/LABA is gradually increasing, while the number of inpatients is decreasing. However, there is still a large gap in the proportion of asthma maintenance medication used in different levels of hospitals, so it is necessary to continuously promote standardized diagnosis and treatment management of asthma in hospitals at all levels, especially primary hospitals.